Cyclosporine as postoperative immunomodulating agent in penetrating keratoplasty for keratomycosis: a case series
DOI:
https://doi.org/10.62856/djcro.v8.55Abstract
Purpose:
This study evaluates the efficacy and safety of topical cyclosporine A (tCSA) 2% as an immediate postoperative immunosuppressant following penetrating keratoplasty (PKP) for fungal keratitis to reduce graft rejection and fungal recurrence.
Methods:
A retrospective case series at Duke Eye Center included six patients who underwent PKP for keratomycosis (2023–2024). Patients received tCSA 2% for at least one week before transitioning to topical prednisolone. Outcomes included graft rejection, fungal recurrence, visual acuity, and corneal clarity over six months.
Results:
Five distinct fungal pathogens were identified; no fungal recurrence or graft rejection occurred. Surgical outcomes were favorable, with tCSA treatment lasting 3–24 weeks, allowing for delay of prednisolone initiation.
Conclusion:
tCSA may help manage inflammation while minimizing fungal recurrence, serving as a bridge to corticosteroids. These findings support its potential role in postoperative PKP care, warranting further research for standardized protocols.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
The Contributor assigns to Duke, during the full term of copyright and any extensions or renewals, all copyright in and to the Manuscript, and all rights therein, including but not limited to the right to publish, republish, transmit, sell, distribute and otherwise use the Manuscript in whole or in part in electronic editions of the DJCRO and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so. "Manuscript" means the article submitted by the Contributor for publication in the DJCRO (including any embedded rich media) and all subsequent versions. The definition of Manuscript does not extend to any supporting information submitted with or referred to in the Manuscript ("Supporting Information"). To the extent that any Supporting Information is submitted to the DJCRO, Duke is granted a perpetual, non-exclusive license to publish, republish, transmit, sell, distribute and otherwise use this Supporting Information in whole or in part in electronic and print editions of the DJCRO and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so. If the Manuscript was shared as a preprint, the Contributor grants to Duke exclusivity as to any rights retained by the Contributor in the preprint.
Reproduction, posting, transmission or other distribution or use of the final Manuscript in whole or in part in any medium by the Contributor as permitted by this Agreement requires a citation to the DJCRO suitable in form and content as follows: (Contributor(s), Title of Manuscript, Journal Title, Journal Volume, Copyright© [year], Digital Object Identifier [DOI] link to final Manuscript). Links to the final article on the DJCRO website are also encouraged where appropriate.
